Factors in Late Hospice Admission for Cancer Identified

Share this content:
Late admission more likely for younger patients, married men, hematologic malignancies.
Late admission more likely for younger patients, married men, hematologic malignancies.

For patients with cancer, factors associated with late admission to hospice have been identified, according to a study published online in the Journal of Clinical Oncology.

Nina R. O'Connor, M.D., from the University of Pennsylvania, and colleagues evaluated electronic health records for patients with cancer admitted to 12 hospices in the Coalition of Hospices Organized to Investigate Comparative Effectiveness network. The authors examined patient characteristics associated with hospice enrollment in the last three days of life.

RELATED: Hospice and the Oncology Patient: Why So Much Confusion?

The researchers found that 16.3 percent of the 64,264 patients admitted to hospice with cancer had a length of stay of three days or less. The proportion of patients enrolled in the last three days of life varied considerably among hospices (range, 11.4 to 24.5 percent).

In multivariable analysis, patients who were admitted in the last three days of life were more likely to have a hematologic malignancy; were more likely to be male and married; and were younger (age < 65 years). Admission to hospice within three days of death was less likely for those with Medicaid or self-insurance.

"Quality measures of hospice lengths of stay should include patient-mix adjustments for type of cancer and site of care," the authors write.

  1. O'Connor, Nina R., et al. "Hospice Admissions for Cancer in the Final Days of Life: Independent Predictors and Implications for Quality Measures." Journal of Clinical Oncology. doi: 10.1200/JCO.2014.55.8817. August 25, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs